C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics cash
Cash and short-term investments held at the end of each period.
C4 Therapeutics's cash was $274.70M at Sep 30, 2026. For fiscal 2025 it was $297.10M, up 11.1% from the year before. The highest annual figure on record is $451.50M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $297.10M | +11.1% |
| FY2024 | Dec 31, 2024 | $267.30M | -5.1% |
| FY2023 | Dec 31, 2023 | $281.70M | -16.4% |
| FY2022 | Dec 31, 2022 | $337.10M | -25.3% |
| FY2021 | Dec 31, 2021 | $451.50M | +21.5% |
| FY2020 | Dec 31, 2020 | $371.70M | +310.5% |
| FY2019 | Dec 31, 2019 | $90.55M | +132.8% |
| FY2018 | Dec 31, 2018 | $38.89M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $274.70M | +37.5% |
| Q2 FY2026 | Jun 30, 2026 | $300.40M | +34.7% |
| Q1 FY2026 | Mar 31, 2026 | $268.30M | +14.3% |
| Q4 FY2025 | Dec 31, 2025 | $297.10M | +11.1% |
| Q3 FY2025 | Sep 30, 2025 | $199.80M | -29.7% |
| Q2 FY2025 | Jun 30, 2025 | $223.00M | -24.6% |
| Q1 FY2025 | Mar 31, 2025 | $234.70M | -21.6% |
| Q4 FY2024 | Dec 31, 2024 | $267.30M | -5.1% |
| Q3 FY2024 | Sep 30, 2024 | $284.40M | +15.4% |
| Q2 FY2024 | Jun 30, 2024 | $295.70M | +3.1% |
| Q1 FY2024 | Mar 31, 2024 | $299.20M | -1.9% |
| Q4 FY2023 | Dec 31, 2023 | $281.70M | -16.4% |
| Q3 FY2023 | Sep 30, 2023 | $246.40M | -32.7% |
| Q2 FY2023 | Jun 30, 2023 | $286.70M | -27.9% |
| Q1 FY2023 | Mar 31, 2023 | $305.00M | -27.7% |
| Q4 FY2022 | Dec 31, 2022 | $337.10M | -25.3% |
| Q3 FY2022 | Sep 30, 2022 | $366.00M | -23.8% |
| Q2 FY2022 | Jun 30, 2022 | $397.80M | -20.2% |
| Q1 FY2022 | Mar 31, 2022 | $421.70M | +21.9% |
| Q4 FY2021 | Dec 31, 2021 | $451.50M | +21.5% |
| Q3 FY2021 | Sep 30, 2021 | $480.30M | +140.9% |
| Q2 FY2021 | Jun 30, 2021 | $498.70M | +363.3% |
| Q1 FY2021 | Mar 31, 2021 | $346.00M | +368.5% |
| Q4 FY2020 | Dec 31, 2020 | $371.70M | +310.5% |
| Q3 FY2020 | Sep 30, 2020 | $199.40M | +97.5% |
| Q2 FY2020 | Jun 30, 2020 | $107.65M | +176.8% |
| Q1 FY2020 | Mar 31, 2020 | $73.86M | – |
| Q4 FY2019 | Dec 31, 2019 | $90.55M | – |
| Q3 FY2019 | Sep 30, 2019 | $100.97M | – |
| Q4 FY2018 | Dec 31, 2018 | $38.89M | – |
See a number that looks wrong?